TCT

This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures. 

The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation | November 02, 2017
November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the...
The B. Braun Sequent Please drug-eluting balloon.

An illustration of the Sequent Please drug-coated balloon.

Feature | Drug-Eluting Balloons | November 02, 2017
November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug-...
Study Examines Use of CrossBoss Catheter for Chronic Total Occlusion PCI
News | Chronic Total Occlusion (CTO) | November 02, 2017
November 2, 2017 — Crossing the occlusion with a guidewire is often the most challenging part of chronic total...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017
November 1, 2017 — OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the...
Double Kissing Crush Two-Stent Technique in Left Main Bifurcation Lesions Demonstrates Lower Target Lesion Failure Rates
News | Stents Bifurcation | November 01, 2017
November 1, 2017 — The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion...
Analytics 4 Life Presents Clinical Data on Machine-Learned Cardiac Imaging Technology at TCT 2017
News | Cardiac Diagnostics | November 01, 2017
November 1, 2017 — Analytics 4 Life announced it will be presenting new clinical data on the company's ongoing Coronary...
TAVR Cost-Effective Compared With SAVR in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 01, 2017
November 1, 2017 — Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter...
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strategy...
The Boston Scientific FilterWire EZ embolic protec filter system.

The Boston Scientific FilterWire EZ embolic protection system.

News | Embolic Protection Devices | October 31, 2017
October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the...
Sapien 3 Valve Demonstrates Significant Cost Savings Over Surgery In Intermediate-Risk Patients
News | Heart Valve Technology | October 31, 2017
October 31, 2017 — Edwards Lifesciences Corp. announced new data demonstrating substantial economic advantages of the...
Thirty-Day ABSORB IV Results Demonstrate Improvements Still Needed in Bioresorbable Stents
News | Stents Bioresorbable | October 31, 2017
October 31, 2017 – Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular...
FDA Investigating Increased Major Adverse Cardiac Event Rates of Absorb Bioresorbable Stent
News | Stents Bioresorbable | October 31, 2017
October 31, 2017 — The U.S. Food and Drug Administration (FDA) issued a warning to healthcare providers that interim...
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab | October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left...
Materialise Announces Start of Pre-Market Phase for Mitral Valve Planning
News | Medical 3-D Printing | October 30, 2017
October 30, 2017 — Entering their pre-market phase of development, Materialise is working with select U.S. and EU...
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
October 27, 2017 — CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion...